10-K: Xtant Medical Holdings Reports Increased Revenue but Net Loss for Fiscal Year 2024

Xtant Medical Holdings, Inc. reports a revenue increase for fiscal year 2024 driven by acquisitions and licensing agreements, but also reports a net loss due to increased operating expenses and interest expense.

Summary

• Xtant Medical Holdings, Inc. reported a revenue increase of 28% for the year ended December 31, 2024, reaching $117.3 million compared to $91.3 million in the prior year.
• The revenue growth was primarily driven by the acquisition of Surgalign Holdings' hardware and biologics business, higher independent agent sales, and $1.5 million in upfront licensing revenue.
• The company incurred a net loss of $16.4 million for the year ended December 31, 2024, compared to a net income of $660 thousand in the prior year.
• The net loss was primarily due to increased operating expenses, interest expense, and the absence of a $11.7 million gain on bargain purchase recognized in 2023.
• Cost of sales increased by 37% to $49.1 million, attributed to higher revenue and a $1.5 million inventory write-off related to the Surgalign Holdings acquisition.
• Operating expenses increased by 22% to $80.3 million, driven by higher sales and marketing expenses, general and administrative expenses, and research and development expenses.
• The company entered into two license agreements with distributors for its SimpliMax and SimpliGraft products, receiving upfront payments of $1.5 million each and anticipating future royalty payments.
• A CMS policy change may impact the revenue generated from these license agreements.
• As of December 31, 2024, the company had $34.2 million of principal outstanding under its Credit Agreements.
• The company believes its cash and cash equivalents, restricted cash, and existing credit availability will be sufficient to meet its anticipated cash requirements through at least the end of March 2026.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with revenue growth offset by a net loss and potential risks. The sentiment is neutral as the positive and negative aspects balance each other out.

Positives

• Revenue increased by 28% due to acquisitions and licensing agreements.
• The company secured upfront payments of $1.5 million each for SimpliMax and SimpliGraft license agreements.
• The company anticipates $3.75 million in guaranteed minimum royalty payments for SimpliMax and $3.9 million in minimum purchase obligations for SimpliGraft during 2025.
• The company believes it has sufficient cash to operate until March 2026.
• The company has over 670 independent sales agents and stocking agents as of December 31, 2024.

Negatives

• The company reported a net loss of $16.4 million for fiscal year 2024.
• Cost of sales increased by 37% due to higher revenue and inventory write-offs.
• Operating expenses increased by 22% due to higher sales and marketing expenses, general and administrative expenses, and research and development expenses.
• A CMS policy change may negatively impact the revenue generated from the SimpliMax and SimpliGraft license agreements.

Risks

• The company's future revenues may be affected by the implementation of a CMS policy change.
• The company may need additional financing to satisfy future liquidity requirements.
• The company has significant indebtedness under its Credit Agreements, which contain certain affirmative and restrictive covenants, with which it has had difficulty complying during the past few years.
• The company is dependent on key suppliers of raw materials, which puts it at risk of interruptions in the availability of its products.
• The company operates in some markets outside the United States that are subject to political, economic, and social instability and expose it to additional risks.
• The company's biologics business is highly dependent on the availability of human donors and negative publicity could reduce demand for its biologics products and impact the supply of available donor tissue.

Future Outlook

The company anticipates future royalty payments from licensing agreements and plans to continue pursuing key growth initiatives, but a CMS policy change may impact revenue from these agreements.

Industry Context

The orthopedic biomaterials market consists of materials that are organic, inorganic or synthetic in nature. These materials are implanted or applied in or near the indicated bone to aid in healing, encourage bone tissue augmentation, compensate in areas where bone tissue is depleted, and restore structure to allow for repair. These materials are often used as substitutes to autograft materials, which are taken from a harvest site in the patient to patch or repair the wounded or unhealthy site. Fixation is often instrumental in allowing the body to heal and regenerate tissue. Fixation provides the constructive support necessary for reestablishing stability, by immobilizing the regenerative site, and relieving stress. Fixation also can help hold the biomaterial in place in order to achieve a better outcome. Examples of fixation products can include, but are not limited to, plates, screws, pins, rods, spacers, and staples. Fixation products may be made from various metals and polymer materials. Conversely, motion preservation devices are designed predominantly to stabilize the spine and allow for motion of the segments. Spine implants can be surgically applied via traditional open surgery or via minimally invasive surgery. We provide devices in both the fixation and motion preservation categories of the spine implant market and via both surgical methodologies.

Comparison to Industry Standards

• The company's primary competitors include Medtronic plc, Johnson and Johnson, Zimmer Biomet Holdings, Inc., Stryker Corporation, Bioventus Inc., Globus Medical, Inc., OrthoFix Medical Inc., Alphatec Holdings, Inc., Highridgek Inc., SI-Bone Inc., as well as dozens of privately-owned companies.
• The company also competes with tissue banks that do not offer spinal fixation products, such as AlloSource International, Inc., LifeNet Health, and MTF Biologics.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the net loss and potential dilution from future capital raises.
• Employees may be affected by potential cost-cutting measures or restructuring.
• Customers may benefit from new product releases and expanded distribution networks.
• Suppliers may see increased demand due to revenue growth.

Next Steps

• The company plans to release FibreX next generation advanced DBM Fiber, OsteoFactor Pro internally produced solubilized allogenic growth factor cocktail stabilized by native human collagen, and TriviumFX, designed for bone regeneration, combining advanced science with practical application during 2025.

Key Dates

Keywords

revenue, acquisitions, licensing agreements, net loss, financial results, medical devices, orthobiologics, spinal implants, Surgalign, SimpliMax, SimpliGraft, CMS policy, credit agreements, RTI, nanOss